Management and Treatment Outcomes of High-Risk Corneal Transplantations

Urbańska, Karolina; Woźniak, Marcin; Więsyk, Piotr; Konarska, Natalia; Bartos, Weronika; Biszewski, Mateusz; Bielak, Michał; Chorągiewicz, Tomasz; Rejdak, Robert

doi:10.3390/jcm11195511

Open AccessArticle

Management and Treatment Outcomes of High-Risk Corneal Transplantations

by

Karolina Urbańska

,

Marcin Woźniak

,

Piotr Więsyk

,

Natalia Konarska

,

Weronika Bartos

,

Mateusz Biszewski

,

Michał Bielak

,

Tomasz Chorągiewicz

^* and

Robert Rejdak

Chair and Department of General and Pediatric Ophthalmology, Medical University of Lublin, 20-079 Lublin, Poland

^*

Author to whom correspondence should be addressed.

J. Clin. Med. 2022, 11(19), 5511; https://doi.org/10.3390/jcm11195511

Submission received: 18 August 2022 / Revised: 14 September 2022 / Accepted: 16 September 2022 / Published: 20 September 2022

(This article belongs to the Special Issue Treatment of Cornea and Ocular Surface Diseases)

Download

Browse Figures

Review Reports Versions Notes

Abstract

Corneal transplantation is the most effective treatment for corneal blindness. Standard planned keratoplasties have a high success rate. Conditions such as active inflammation at the time of surgery, the presence of ocular surface disease, previous graft disease, or neovascularization make them more susceptible to rejection. These are so-called high-risk corneal transplantations. In our study, we selected 52 patients with a higher risk of graft rejection. A total of 78 procedures were performed. The main indications for the first keratoplasty were infections (59.6%) and traumas (21.2%). Visual acuity (VA) significantly improved from 2.05 logMAR on the day of keratoplasty to 1.66 logMAR in the latest examination (p = 0.003). An analysis of the graft survival showed a 1-year survival of 54% and a 5-year survival of 19.8% of grafts. The mean observation time without complications after the first, second, and third surgery was 23, 13, and 14 months, respectively. The best results were noted among patients with infectious indications for keratoplasty (p = 0.001). Among them, those with bacterial infection had the best visual outcomes (p = 0.047).

Keywords: cornea; corneal transplantation; high-risk corneal transplantation; keratoplasty; immunosuppression in corneal transplantation; corneal immune privilege

Graphical Abstract

Share and Cite

MDPI and ACS Style

Urbańska, K.; Woźniak, M.; Więsyk, P.; Konarska, N.; Bartos, W.; Biszewski, M.; Bielak, M.; Chorągiewicz, T.; Rejdak, R. Management and Treatment Outcomes of High-Risk Corneal Transplantations. J. Clin. Med. 2022, 11, 5511. https://doi.org/10.3390/jcm11195511

AMA Style

Urbańska K, Woźniak M, Więsyk P, Konarska N, Bartos W, Biszewski M, Bielak M, Chorągiewicz T, Rejdak R. Management and Treatment Outcomes of High-Risk Corneal Transplantations. Journal of Clinical Medicine. 2022; 11(19):5511. https://doi.org/10.3390/jcm11195511

Chicago/Turabian Style

Urbańska, Karolina, Marcin Woźniak, Piotr Więsyk, Natalia Konarska, Weronika Bartos, Mateusz Biszewski, Michał Bielak, Tomasz Chorągiewicz, and Robert Rejdak. 2022. "Management and Treatment Outcomes of High-Risk Corneal Transplantations" Journal of Clinical Medicine 11, no. 19: 5511. https://doi.org/10.3390/jcm11195511

APA Style

Urbańska, K., Woźniak, M., Więsyk, P., Konarska, N., Bartos, W., Biszewski, M., Bielak, M., Chorągiewicz, T., & Rejdak, R. (2022). Management and Treatment Outcomes of High-Risk Corneal Transplantations. Journal of Clinical Medicine, 11(19), 5511. https://doi.org/10.3390/jcm11195511

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Management and Treatment Outcomes of High-Risk Corneal Transplantations

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI